Systemic antimicrobial agents. Macrolides
Clarithromycin is a semi-synthetic antibiotic of the macrolide group. The antibacterial action of clarithromycin is determined by its binding to the 5OS ribosomal subunit of susceptible bacteria and inhibition of protein biosynthesis.
Treatment of infections caused by clarithromycin-sensitive microorganisms.
– Upper respiratory infections, e.g. nasopharynx (tonsillitis, pharyngitis) and sinus infections.
– Lower respiratory infections (bronchitis, acute lobar pneumonia, and primary atypical pneumonia).
– Skin and soft tissue infections (impetigo, folliculitis, erysipeloid, furunculosis, infected wounds).
– Acute and chronic odontogenic infections.
– Disseminated or localised mycobacterial infections caused by Mycobacterium avium or Mycobacterium intracellulare.Localised infections caused by Mycobacterium chelonae, Mycobacterium fortuitum or Mycobacterium kansasii.
– H. pylori eradication in patients with duodenal ulcers when hydrochloric acid secretion is inhibited (clarithromycin activity against H. pylori is higher at neutral pH than at acidic pH).
Clarithromycin tablets should be taken orally, without chewing, with a small amount of water. The medicine can be used regardless of food intake, since food does not affect clarithromycin bioavailability.
The recommended dose of clarithromycin for adults and children over 12 is 250 mg every 12 hours, in more severe infections the dose may be increased to 500 mg every 12 hours. The usual duration of treatment depends on the degree and severity of infection and ranges from 6 to 14 days.
Clarithromycin-Darnitsa can be used in children over 12.
In children under the age of 12 years, clarithromycin must be administered in another dosage form (suspension).